New combo therapy aims to shrink advanced tumors
NCT ID NCT07131202
First seen Jan 09, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About 130 adults aged 18-80 will receive the drugs by IV. This is an early-phase trial focused on safety and tumor control, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.